Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
veganism.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
Veganism Social is a welcoming space on the internet for vegans to connect and engage with the broader decentralized social media community.

Administered by:

Server stats:

272
active users

veganism.social: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.4.0-alpha.5

#CovidIsNotOver

60 posts54 participants6 posts today
Public
Tom Kindlon

"3.4% of adults reported long COVID. Adults with long #COVID more often reported being unable to work due to health or disability compared to adults without #longCOVID (p=0.0006)."

onlinelibrary.wiley.com/doi/ab

Screenshot from latest Science for ME weekly update

Hashtags:
@longcovid
#PASC #PwLC #postcovid #postcovid19 #Covidlonghaulers #PostCovidSyndrome #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID19 #COVID_19 #COVIDー19 #SARSCoV2 @novid@chirp.social #novid @novid@a.gup.pe #CovidIsNotOver
@auscovid19 #auscovid19

Employment Status, Work Limitations, Cognitive Dysfunction, and Sickness Absenteeism Among US Adults With and Without Long COVID — Nicole D. Ford et al. "3.4% of adults reported long COVID. Adults with long COVID more often reported being unable to work due to health or disability compared to adults without long COVID (p = 0.0006)."
Public
Tom Kindlon

"Substantial increases were observed in primary healthcare consultations in 2024 compared to prepandemic levels. Many of the conditions with the greatest excess are associated with post-acute #COVID19 sequelae"

researchsquare.com/article/rs-

Screenshot from Science for ME update

Hashtags:
@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #Covidlonghaulers #PostCovidSyndrome #COVIDBrain #NeuroPASC @covid19 #Coronavirus #COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2 #CovidIsNotOver @auscovid19

Excess primary healthcare consultations in Norway in 2024 compared to pre-COVID-19-pandemic baseline trends — Richard Aubrey White et al. "Substantial increases were observed in primary healthcare consultations in 2024 compared to prepandemic levels. Many of the conditions with the greatest excess are associated with post-acute COVID-19 sequelae."
Public *
datum (n=1)

One for the "SARS-CoV-2 and Cancer" pile: bmcinfectdis.biomedcentral.com

a clear dose-dependent relationship between COVID-19 severity and genomic instability

in detail:

Post-COVID-19 patients exhibited significantly higher levels of DNA damage compared to healthy controls. The highest DNA damage was observed in intubated-ICU patients (mean DNA damage: 29.5%), followed by non-intubated-ICU patients (mean: 24.3%), non-ICU patients (mean: 19.1%), and healthy controls (mean: 9.4%).

also buried in the article:

47% of those [after acute COVID-19] who did not require such ventilation [intubation] displayed significant, prolonged reductions in pulmonary function

via disabled.social/@tomkindlon/11

BioMed CentralThe silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors - BMC Infectious DiseasesBackground Persistent symptoms and complications reported by many patients for more than four weeks after contracting coronavirus disease 2019 (COVID-19) are referred to as post-COVID-19 syndrome. These persistent symptoms can occur in individuals with both mild and severe COVID-19, though the underlying pathophysiological mechanisms remain poorly understood. This study aims to explore post-COVID-19 syndrome from a biological perspective, focusing on genomic instability. Methods In this cross-sectional study, the comet assay method was employed in March 2024 to evaluate the level of DNA damage in 29 patients to examine the post-COVID-19 syndrome state at Kausar Semnan Hospital in Iran. Levels of DNA damage were assessed using the alkaline comet assay in patients hospitalized for COVID-19, four weeks after a positive RT-PCR test. Patients were categorized based on pneumonia severity: mild (11 patients in non-ICU), moderate (10 patients in ICU and non-intubated), and severe/critical (8 patients in ICU and intubated). Ten healthy individuals who tested negative for COVID-19 were considered as a control group. Data were analyzed using descriptive and inferential statistical tests at a significance level of p < 0.01 in GraphPad Prism 9 software. Results Post-COVID-19 patients exhibited significantly higher levels of DNA damage compared to healthy controls. The highest DNA damage was observed in intubated-ICU patients (mean DNA damage: 29.5%), followed by non-intubated-ICU patients (mean: 24.3%), non-ICU patients (mean: 19.1%), and healthy controls (mean: 9.4%). These findings suggest a clear correlation between COVID-19 severity and increased genomic instability. Conclusion The results of this study highlight the prevalence of DNA damage in post-COVID-19 patients, which may explain long-term genomic instability and associated health complications. The findings underscore the importance of further research into the pathophysiological mechanisms of post-COVID-19 syndrome, particularly its impact on genomic stability. This study contributes to the growing evidence that post-COVID-19 syndrome is a complex condition with virus-specific abnormalities affecting multiple biological pathways. Future studies should focus on understanding these mechanisms to develop targeted interventions for long-term COVID-19 survivors.
#COVID#COVID19#SARSCoV2
Public
Jeri Dansky

RFK Jr possibly/probably banning mRNA Covid vaccines in the near future? What an atrocious thing to do, leading to more death and long-term disability. The vaccines are such an amazing achievement, and he wants to toss that all away.

Since I'm probably flying to Florida in mid-December for my dad's 101st birthday, I really wanted to wait until at least mid-September to get my next Covid booster. (My last one was in January.) I think that should still be OK, but who knows for sure?

And after that I guess I'll just be continuing all my Covid-avoiding behaviors. Not that I had any plans to back off, anyway.

thedailybeast.com/donald-trump or
archive.vn/btTUl

Robert F Kennedy Jr. and Donald Trump behind a medical gloved hand holding vaccine vial wrapped in barbed wire
The Daily Beast · Trump and RFK Jr. to Ban COVID-19 Vaccine ‘Within Months’By Tom Latchem
#Covid#Covid19#CovidIsNotOver
Continued thread
Public
datum (n=1)

Someone (you know who you are) pointed this sciencedirect.com/science/arti out

which hints that maybe metformin's mechanism of action against LC might be to make it harder for C19 to establish viral reservoirs

haven't read the paper in depth but a very interesting notion

if true then we could expect to see meformin

  • reducing LC symptom clusters downstream from persistence, but
  • reducing less LC from symptoms downstream from immune dysregulation, direct epithelial and BBB damage, and direct organ damage
www.sciencedirect.comMetformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodiesThe mechanistic target of rapamycin (mTOR) positively regulates multiple steps of the HIV-1 replication cycle. We previously reported that a 12-week s…
#COVID#SARSCoV2#COVID19
Public
Paula Gordon

Unbelievable -- the link for "Find COVID-19 Tests at COVID.gov/tests" at the bottom of the FDA page for test information, fda.gov/medical-devices/corona, redirects to a frickin Covid conspiracy page sponsored by the USGov.
Yup, covid.gov/tests redirects to
whitehouse.gov/lab-leak-true-o
Among other things, it says, "There was no conclusive evidence that masks effectively protected Americans from COVID-19."

#Unfuckingbelievable #CovidConspiracy
#CovidIsNotOver #MaskUp #CovidIsAirborne

U.S. Food and Drug Administration · At-Home OTC COVID-19 Diagnostic TestsExpiration dates and more about authorized at-home OTC COVID-19 diagnostic tests information.
Public *
datum (n=1)

So I'm reading medrxiv.org/content/10.1101/20 with interest as it ostensibly found metformin didn't meaningfully decrease Long COVID rates

and

participants didn't receive the metformin until a median five days after symptom onset

they cite other work that found a ~40% reduction in LC with metformin dose:

In the COVID-OUT randomized trial, the HR for participant-reported clinician diagnosis of LC in those randomized to 14 days of metformin was 0.59 (95% CI 0.39 to 0.89)

and I am left wondering if maybe "metformin should be taken as early as possible during acute COVID-19" is what the new study really suggests

medRxiv · Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical TrialBackground The effect of metformin on preventing long-term COVID-19 symptoms among low-risk adults has not been studied. The objective of this study was to Assess metformin compared with placebo during acute SARS-CoV-2 infection on the presence of COVID-19 symptoms 180 days later. Methods The ACTIV-6 platform evaluated repurposed medications for mild to moderate COVID-19. Between September 19, 2023 and May 1, 2024, 2983 outpatient adults ≥30 years with confirmed SARS-CoV-2 infection and ≥2 COVID-19 symptoms for ≤7 days were included from 90 sites. Participants were randomized to metformin (titrated to 1500 mg daily) or placebo for 14 days. Post-acute sequelae of SARS-CoV-2 or death (PASCD) was ascertained by asking whether participants had symptoms they attributed to COVID-19 on day 180. Secondary outcomes included clinician diagnosis of long COVID. For the primary outcome, the single-sided threshold for efficacy was 0.975. Results Among 2983 participants, the median age was 47 years (interquartile range [IQR] 38–57); 63% were female; 47% Hispanic/Latino; 83% reported ≥1 prior COVID-19 infections or SARS-CoV-2 vaccines. There were no deaths. Overall, 96 (3.2%) reported COVID-19 symptoms on day 90, 101 (3.4%) on day 120, and 79 (2.6%) on day 180. The covariate-adjusted risk of PASCD on day 180 was lower in the metformin group (−0.008; 95% credible interval [CrI] −0.022 to 0.006; posterior probability of efficacy [PPE] 0.83), compared with the placebo group with an adjusted risk ratio of 0.79 (95% CrI 0.474 to 1.230). The risk of clinician diagnosis of long COVID (secondary outcome) on day 180 was lower in the metformin group (−0.007; 95% CrI −0.015 to 0.001; PPE 0.96), with a relative risk of 0.495 (95% CrI 0.155 to 0.995). Conclusions The posterior probability of efficacy for metformin preventing the primary endpoint did not exceed the prespecified threshold of 0.975 for declaring efficacy. Secondary outcomes were numerically better with metformin. Trial Registration [ClinicalTrials.gov][1] ([NCT04885530][2]). ### Competing Interest Statement Bramante: Reports grants from the NIH outside the current work during the conduct of the study. Stewart: Reports grants from NIH NCATS during the conduct of the study; Grants from NIH outside the submitted work. Boulware: Reports grants from NIH during the conduct of the study. McCarthy: Nothing to report. Gao: Nothing to report. Rothman: Reports grants from NIH, PCORI, AHRQ, CDC, CardioHealth Alliance during the conduct of the study. Spouse owns stock in Moderna unrelated to the current work. Mourad: Nothing to report. Thicklin: Nothing to report. Cohen: Nothing to report. Garcia del Sol: Nothing to report. Shah: Nothing to report. Mehta: Nothing to report. Cardona: Nothing to report. Scott: Nothing to report. Ginde: Reports grants from NIH during the conduct of the study; Grants from NIH, CDC, DoD, AbbVie (investigator-initiated), and Faron Pharmaceuticals (investigator-initiated) outside the submitted work. Castro: Reports institutional grant funding from NIH, ALA, PCORI, AstraZeneca, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi; Speaker/Consultant fees from Grant Funding, Genentech, Teva, Sanofi-Aventis; Consultant fees from Merck, Novartis, Arrowhead, OM Pharma, Allakos; Speaker honorarium from Amgen, AstraZeneca, GSK, Regeneron; Royalties from Elsevier all outside the submitted work. Jayaweera: Reports grants from NCATS during the study; Grants from Gilead, Pfizer, Janssen, and ViiV. advisory board fees from ViiV and Theratechnologies outside the submitted work. Sulkowski: Reports advisory board fees from AbbVie, Gilead, GSK, Atea, Antios, Precision Bio, Viiv, and Virion; Institutional grants from Janssen outside the submitted work. Gentile: Reports personal fees from Duke University for protocol development and oversight during the conduct of the study; grants from NIH outside the submitted work. McTigue: Reports grants from NIH to the University of Pittsburgh during the conduct of the study; Research contracts to the University of Pittsburgh from Pfizer, Eli Lilly, and Janssen outside the submitted work. Felker: Reports institutional research grants from NIH during the conduct of the study and from Novartis outside the submitted work. Collins: Reports grant funding from NHLBI and personal fees from Vir Biotechnology during the conduct of the study. Dunsmore: Nothing to report. Adam: Reports other from US Government Funding through Operation Warp Speed during the conduct of the study. Lindsell: Reports institutional grants from NCATS during the conduct of the study; Institutional grants from NIH, CDC, and DoD; Contract with institution for research services from Endpoint Health, bioMerieux, Entegrion Inc, Abbvie, and Astra Zeneca, Biomeme, and Novartis outside the submitted work; Dr Lindsell has a patent for risk stratification in sepsis and septic shock issued to Cincinnati Children's Hospital Medical Center. Hernandez: Reports grants from American Regent, Amgen, Boehringer Ingelheim, Merck, Verily, Somologic, and Pfizer; Personal fees from AstraZeneca, Boston Scientific, Cytokinetics, Bristol Myers Squibb, and Merck outside the submitted work. Naggie: Reports grants from NIH, the sponsor for this study, during the conduct of the study; Institutional research grants from Gilead Sciences, AbbVie; Consulting fees from Pardes Biosciences; Scientific advisor/Stock options from Vir Biotechnology; Consulting with no financial payment from Silverback Therapeutics; DSMB fees from Personal Health Insights, Inc; Event adjudication committee fees from BMS/PRA outside the submitted work. ### Clinical Trial NCT04885530 ### Funding Statement Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 is supported with CARES ACT and American Rescue Plan Act funds awarded through grants 3U24TR001608-05S4, 3U24TR001608-06S1 and 3U24TR001608-07S1 from the National Center for Advancing Translational Sciences (NCATS). Additional support for this study was provided by contract 75A50122C00037 from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority. Vanderbilt University Medical Center Clinical and Translational Science Award UL1TR002243 from NCATS supported the REDCap infrastructure. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: WCG IRB gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ACTIV-6 is a platform trial using shared placebos. On completion of the platform trial, when there is no risk of unblinding across study arms, the data will be made publicly available by depositing it in an approved data repository such as NHLBI BioData Catalyst. [1]: https://ClinicalTrials.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04885530&atom=%2Fmedrxiv%2Fearly%2F2025%2F08%2F12%2F2025.08.08.25333305.atom
#SARSCoV2#COVID#COVID19
Replied in thread
Public
Huskify

@Maxfieldripken 😱What a nightmare when there is an ongoing covid wave. This is abominable. Have you considered ordering bulk testing from Europe? I have had good luck with Altruan in Germany. I split the order amongst friends and even with the overseas shipping charge, the cost per test is 1/3 of the cost in the US. Of course, this was before the big mess in the US with tariffs. Should be better in Canada. altruan.com/products/cordx-4-i
#CovidIsNotOver

altruan.comCordx 4 in 1 lay-antigen combination test RSV viruses + corona Covid-19 + influenza A + B | Pack (1 test)
Replied in thread
Public
datum (n=1)

People with long COVID reported worse disability than 98% of the general Australian population. A total of 86% of those with long COVID met the threshold for serious disability compared with 9% of Australians overall.

theconversation.com/long-covid

h/t @trendless

The ConversationLong COVID is more than fatigue. Our new study suggests its impact is similar to a stroke or Parkinson’s
More from The Conversation AU + NZ
#COVID#COVID19#SARSCoV2
Public
Trenton Hoshiko | Filmmaker

My good friend has covid for the 1st time in a while (thankfully) so I sent a bunch of reminder info about masking, isolating, hydration, how antivirals can be an option, & to have 2 neg tests 36+ hrs apart to try to catch rebounds/false negs. Tried to keep it focused on effectiveness & not overwhelming.
Ended my message with "Info dumping a bit, but if our government isnt gonna do public health to protect my friends, I will" They said they appreciated it :)

#CovidIsNotOver#WearAMask
Public
Tom Kindlon

Low Dose Naltrexone (LDN) for the treatment of people with ME: A Conversation with Dr Etianne Sasso,

Dr Sasso is from NCNED (in Australia), who are recruiting for an #LongCovid LDN trial & will soon be recruiting for a #MEcfs LDN trial 

forums.phoenixrising.me/thread

@mecfs @longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC #postcovid
#CovidBrain
@covid19 #COVIDー19 #COVID19 #COVID #COVID_19 #SARSCoV2 @
#CovidIsNotOver #auscovid19 @auscovid19

Phoenix Rising ME/CFS ForumsDISCUSSION: Low Dose Naltrexone for the treatment of people with ME: A Conversation with Dr Etianne SassoThe UK government has, after numerous delays, finally published its care plan for people with ME which afflicts over 400,000 people. Part of the plan includes increased funding for research, awarded through the National Institute for Health and Care Research, into how existing medicines can be...
VegansExploreLive feeds
About